JYPC(SZ:002198) Zheng Quan Zhi Xing·2025-08-03 16:18Core Viewpoint - Guangdong Jiaying Pharmaceutical Co., Ltd. is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, leading to potential administrative penalties [1][2]. Summary by Sections Investigation and Allegations - The CSRC issued a notice of investigation due to Jiaying Pharmaceutical's alleged violations of information disclosure laws, specifically related to transactions with its related party, Hunan Yaojuneng Pharmaceutical Co., Ltd. [1][2]. - Between October 2024 and January 2025, Jiaying Pharmaceutical's subsidiary provided short-term loans to Hunan Yaojuneng, totaling CNY 219.99 million, which accounted for 28.83% of Jiaying Pharmaceutical's latest audited net assets [2]. Legal Basis and Responsibilities - The actions of Jiaying Pharmaceutical are suspected to violate multiple articles of the Securities Law, including provisions regarding the disclosure of related party transactions [3]. - Key executives, including the chairman and general manager, are identified as directly responsible for the violations, with specific penalties proposed for each individual involved [3][4]. Proposed Penalties - The CSRC plans to impose a warning and a fine of CNY 1.5 million on Jiaying Pharmaceutical, along with individual fines for the chairman (CNY 1.6 million), the general manager (CNY 1 million), and the former financial director (CNY 800,000) [4]. Impact on Operations - Despite the ongoing investigation, Jiaying Pharmaceutical's operations remain normal, and the company asserts that the situation will not significantly impact its business activities [4].